盘龙药业: 2025年半年度募集资金存放与使用情况的专项报告

Core Points - The company has issued a special report on the use of raised funds as of June 30, 2025, ensuring the information is true, accurate, and complete [1] - The company raised a total of RMB 276 million through the issuance of convertible bonds in March 2022 and RMB 301.99 million through a private placement of A-shares in September 2023 [2][5] - The company has established a fund management system to ensure the effective use of raised funds and protect investor rights [2][3] Fundraising Overview - The total amount raised from the convertible bonds was RMB 276 million, with a net amount of RMB 272 million after deducting issuance costs [1] - The total amount raised from the A-share issuance was RMB 301.99 million, with a net amount of RMB 294.84 million after deducting issuance costs [2] - As of June 30, 2025, the company has used a total of RMB 421.71 million of the raised funds, with RMB 155.79 million remaining [5][6] Fund Management and Usage - The company has implemented a dedicated account management system for the raised funds, ensuring compliance with relevant laws and regulations [2][3] - As of June 30, 2025, several fundraising accounts have been closed, and the remaining funds are stored in dedicated accounts [3][4] - The company has not engaged in any temporary use of idle funds for working capital or cash management [5][6] Project Updates and Changes - The "Construction Project of Centralized Preparation Center for Medical Institutions in Shaanxi Province" has been delayed and the completion date has been extended to December 31, 2024, due to various factors [6][9] - The company has decided to terminate the project and use the remaining funds for permanent working capital, following board and supervisory approvals [6][9] - The company has also terminated the "Quality Inspection and Testing Shared Platform Upgrade Project" and redirected the remaining funds to working capital [6][9] Compliance and Disclosure - The company has ensured that all fundraising activities and fund usage have been disclosed in a timely, truthful, accurate, and complete manner [5][6] - There have been no violations in the management of raised funds during the reporting period [5][6]